Azanta CEO: We have money to last to 2017
With EUR 7 million in fresh funding, Denmark-based biotech company Azanta with Genmab co-founder Claus Møller at the helm is in a favorable financial position. An IPO still looms on the horizon.
BY BENJAMIN WERNER CHRISTENSEN
With last week’s financing round providing funding of up to EUR 7 million (DKK 52 million), Danish biotech company Azanta has secured operations until 2017, says Claus Møller, CEO of the company, in an interview with MedWatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Azanta raises EUR 7 million
For abonnenter
